



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/616,760	
			Filing Date	July 9, 2003	
			First Named Inventor	Gelboin, Harry V.	
			Art Unit	Unassigned <b>1644</b>	
			Examiner Name	Unassigned	
Sheet 1	of 3	Attorney Docket Number		015280-389200US	

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
ZS	1	6,623,960	09-23-2003	Gelboin et al.	
ZS	2	5,939,530	08-17-1999	Gelboin et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

ZS

Examiner Signature	/Zachary Skelding/	Date Considered	06/29/2006
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.  
60087612 v1



Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/616,760
				Filing Date	July 9, 2003
				First Named Inventor	Gelboin, Harry V.
				Art Unit	Unassigned 1644
				Examiner Name	Unassigned
Sheet 2 of 3	Attorney Docket Number 015280-389200US				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ZS	3	Eichelbaum et al., "Genetically determined differences in drug metabolism as a risk factor in drug toxicity" Toxicology Letters, 64/65:155-122 (1992).	
ZS	4	Gelboin, H. V., "Cytochrome P450 and monoclonal antibodies," Pharmacol Rev, 45(4):413-453, (1993).	
ZS	5	Gelboin et al., "Inhibitory and noninhibitory monoclonal antibodies to human cytochrome P450 2E1," Chem Res Toxicol, 9(6):1023-1030, (1996).	
ZS	6	Gelboin et al., "Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4," Biochem Pharmacol, 50(11):1841-1850, (1995).	
ZS	7	Gelboin et al., "A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism," Pharmacogenetics, 7:469-477, (1997).	
ZS	8	Gelboin et al., "Methods in Molecular Biology: Cytochrome P450 Protocols," (Phillips and Shephard, eds.) pp. 227-237, Humana Press, (1998).	
ZS	9	Goldfarb et al., "Cross-reactivity of thirteen monoclonal antibodies with ten vaccinia cDNA expressed rat, mouse and human cytochrome P450s," Biochem Pharmacol, 46:787-790, (1993).	
ZS	10	Goldstein et al., "Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans," Biochemistry, 33:1743-1752 (1994)	
ZS	11	Gonzalez, F.J., "Cytochromes P450: Metabolic and Toxicological Aspects," (Ioannides, C., ed.) pp. 183-210, CRC Press (1996)	
ZS	12	Gonzalez et al., "Pharmacogenetic phenotyping and genotyping", Clin. Pharmacokin, 26(1):59-70 (1994).	
ZS	13	Gonzalez et al., "Role of Human Cytochrome P-450s in Risk Assessment and Susceptibility to Environmentally Based Disease," J. Toxicol. and Environmental Health, 40:289-308, (1993).	
ZS	14	Gonzalez et al., "Expression of mammalian cytochrome P450 using vaccinia virus," Methods Enzymol, 206:85-92 (1991a).	
ZS	15	Gonzalez et al., "Expression of mammalian cytochrome P450 using baculovirus," Methods Enzymol, 206:93-99, (1991b).	
ZS	16	Guengerich et al., "Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes," Chem Res Toxicol, 4(4):391-407, (1991).	
ZS	17	Haining et al., "Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and 1359L mutant forms, Arch Biochem Biophys, 333:447-458, (1996)	
ZS	18	Kupfer et al., "Mephenytoin hydrolase deficiency: Kinetics after repeated doses," Clin. Pharmacol. Ther., 35:33 (1984).	

Examiner Signature	/Zachary Skelding/	Date Considered	06/29/2006
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/616,760
		Filing Date	July 9, 2003
		First Named Inventor	Gelboin, Harry V.
		Art Unit	Unassigned 1694
		Examiner Name	Unassigned
Sheet 3 of 3	Attorney Docket Number	015280-389200US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ZS	19	Madsen et al., "Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4," Clin. Pharmacol. Ther., 61:319-324 (1997)	
ZS	20	Miners et al., "Cytochrome P452C9: An enzyme of major importance in human drug metabolism," Br. J. Clin. Pharmacol., 45:525-538 (1998).	
ZS	21	Nasu et al., "Genetic analysis of CYP2C9 polymorphism in a Japanese population, Pharmacogenetics, 7:405-409 (1997).	
ZS	22	Pierce Chemical Company catalogue, "Antibody fragmentation," Rockford IL (1994). <i>Page T21</i>	
ZS	23	Rendic et al., "Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors," Drug Metab. Rev. 29:413-580, (1997).	
ZS	24	Rettie et al., "Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9," Pharmacogenetics, 4:39-42 (1994).	
ZS	25	Rudikoff et al. PNAS, 79:1979-1983 (1982).	
ZS	26	Sai et al., "An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver," Pharmacogenetics, 9:229-237 (1999).	
ZS	27	Shou et al., "Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism" Eur. J. Pharmacol., 394(203):199-209, (2000).	
ZS	28	Sullivan-Klose et al., "The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism, Pharmacogenetics, 6:341-349 (1996).	
ZS	29	Veronese et al., "Tolbutamide and phenytoin hydroxylation's by cDNA-expressed human liver cytochrome P450 2C9, Biochemical Biophysical Research Communications, 175:1112-1118 (1991).	
ZS	30	Washida et al., "Preparation of an activity-inhibiting monoclonal antibody against human placental aromatase cytochrome P450," Steroids, 61:126-132 (1996).	
ZS	31	Yamazaki et al., "7-ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes," Biochem. Pharmacol., 51:313-319 (1996).	
ZS	32	Yamazaki et al., "Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes, Biochem Pharmacol, 56:243-251 (1998).	
ZS	33	Yang et al., "Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin and imipramine metabolism" Drug Metab. Dispos., 27(1):102-109, (1999).	
ZS	34	Yang et al., "Inhibitory monoclonal antibodies to human cytochrome P450 1A2: Analysis of phenacetin O-deethylation in human liver," Pharmacogenetics, 8:375-382 (1998).	

Examiner Signature	/Zachary Skelding/	Date Considered	06/29/2006
--------------------	--------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.